Literature DB >> 22944366

A plant cell-based system that predicts aβ42 misfolding: potential as a drug discovery tool for Alzheimer's disease.

Tiehan Zhao1, Ying Zeng, Allison R Kermode.   

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid β (Aβ) peptides and the failure of mechanisms to clear toxic aggregates. The Aβ42 peptide is considered to be a causative factor that underlies the pathophysiology of AD, in part due to its propensity for misfolding and aggregation; the small oligomers that result represent toxic species. Thus agents that prevent Aβ42 misfolding/aggregation or, alternatively improve Aβ42 oligomer clearance, may have significant therapeutic value. We have developed the basis for a drug screening system based on transgenic plant cells that express Aβ42 fusion proteins to serve as the reliable indicators of the general conformational status of Aβ42. Within cells of transgenic tobacco and Nicotiana benthamiana, misfolding of Aβ42 causes the misfolding of a GFP fusion partner, and consequently there is a loss of fluorescence associated with the native GFP protein. In a similar fusion consisting of Aβ42 linked to hygromycin phosphotransferase II (Hpt II), a hygromycin-resistance marker, misfolding of Aβ42 leads to a misfolded Hpt II, and consequently the transgenic cells are unable to grow on media containing hygromycin. Importantly, substitution of the 'aggregation-prone' Aβ42 with a missense mutant of Aβ42 (F19S/L34F) that is not prone to misfolding/aggregation, 'rescues' both fusion partners. Several 'positive control' chemicals that represent inhibitors of Aβ42 aggregation, including curcumin, epigallocatechin-3-gallate (EGCG), and resveratrol show efficacy in preventing the Aβ42-fusion proteins from misfolding/aggregating in the transgenic plant cells. We discuss the potential of the two fusion protein systems to serve as the basis for an inexpensive, selective, and efficient screening system in which a plant cell can fluoresce or survive only in the presence of drug candidates that are able to prevent Aβ42 misfolding/aggregation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22944366     DOI: 10.1016/j.ymgme.2012.08.010

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

1.  Target-directed discovery and production of pharmaceuticals in transgenic mutant plant cells.

Authors:  D P Brown; D T Rogers; S K Gunjan; G A Gerhardt; J M Littleton
Journal:  J Biotechnol       Date:  2016-09-13       Impact factor: 3.307

Review 2.  Resveratrol and neuroprotection: an insight into prospective therapeutic approaches against Alzheimer's disease from bench to bedside.

Authors:  Fahadul Islam; Mohamed H Nafady; Md Rezaul Islam; Susmita Saha; Salma Rashid; Aklima Akter; Md Harun- Or-Rashid; Muhammad Furqan Akhtar; Asma Perveen; Ghulam Md Ashraf; Md Habibur Rahman; Sherouk Hussein Sweilam
Journal:  Mol Neurobiol       Date:  2022-05-12       Impact factor: 5.590

3.  Novel synthetic chalcone-coumarin hybrid for Aβ aggregation reduction, antioxidation, and neuroprotection.

Authors:  Shin-Ying Lee; Ya-Jen Chiu; Shu-Mei Yang; Chiung-Mei Chen; Chin-Chang Huang; Guey-Jen Lee-Chen; Wenwei Lin; Kuo-Hsuan Chang
Journal:  CNS Neurosci Ther       Date:  2018-09-14       Impact factor: 5.243

4.  Formulated Chinese medicine Shaoyao Gancao Tang reduces NLRP1 and NLRP3 in Alzheimer's disease cell and mouse models for neuroprotection and cognitive improvement.

Authors:  Ya-Jen Chiu; Chih-Hsin Lin; Ming-Chung Lee; Hsiu Mei Hsieh-Li; Chiung-Mei Chen; Yih-Ru Wu; Kuo-Hsuan Chang; Guey-Jen Lee-Chen
Journal:  Aging (Albany NY)       Date:  2021-06-09       Impact factor: 5.682

5.  Potential Benefits of Ameliorating Metabolic and Nutritional Abnormalities in People With Profound Developmental Disabilities.

Authors:  Norris R Glick; Milton H Fischer
Journal:  Nutr Metab Insights       Date:  2017-06-28

6.  Novel TRKB agonists activate TRKB and downstream ERK and AKT signaling to protect Aβ-GFP SH-SY5Y cells against Aβ toxicity.

Authors:  Ya-Jen Chiu; Te-Hsien Lin; Kuo-Hsuan Chang; Wenwei Lin; Hsiu Mei Hsieh-Li; Ming-Tsan Su; Chiung-Mei Chen; Ying-Chieh Sun; Guey-Jen Lee-Chen
Journal:  Aging (Albany NY)       Date:  2022-09-26       Impact factor: 5.955

7.  Neuroprotective Effects of Chronic Resveratrol Treatment and Exercise Training in the 3xTg-AD Mouse Model of Alzheimer's Disease.

Authors:  Tom L Broderick; Suhail Rasool; Rongzi Li; Yuxian Zhang; Miranda Anderson; Layla Al-Nakkash; Jeffrey H Plochocki; Thangiah Geetha; Jeganathan Ramesh Babu
Journal:  Int J Mol Sci       Date:  2020-10-04       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.